By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

VaxInnate Corporation 

3 Cedar Brook Drive
Suite 1
Cranbury  New Jersey  08512  U.S.A.
Phone: 609 860 2260 Fax: 609 860 2290


SEARCH JOBS


Industry
Biotechnology






Company News
VaxInnate Corporation Receives Extension Of Contract From Biomedical Advanced Research and Development Authority (BARDA) For Development Of Seasonal And Pandemic Influenza Vaccines 2/17/2015 7:42:56 AM
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial Of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, In Elderly 12/8/2014 7:55:40 AM
VaxInnate Corporation Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints 11/11/2014 7:14:11 AM
VaxInnate Corporation Updates Plans To Advance Lead Vaccine Candidate, VAX2012Q In Elderly 10/8/2014 7:25:51 AM
Well-Capitalized VaxInnate Corporation Gets Another $6 Million For Its Bacteria-Based Flu Vaccines 10/3/2014 8:00:33 AM
VaxInnate Corporation Begins Phase I Clinical Trial To Evaluate Quadrivalent Vaccine For Prevention Of Seasonal Flu 3/19/2014 8:59:31 AM
VaxInnate Corporation Receives $2.1 Million From New Jersey’s Technology Business Tax Certificate Transfer Program 1/28/2014 9:40:49 AM
VaxInnate Corporation Awarded U.S. Government Grant to Develop Dengue Vaccine 4/4/2013 11:44:13 AM
VaxInnate Corporation’s License Agreement With Emergent BioSolutions (EBS) Improves U.S. Preparedness for Potential Flu Pandemics 1/16/2013 9:32:44 AM
Emergent BioSolutions (EBS) Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate 1/2/2013 9:21:54 AM
1234
//-->